On September 29, 2025 Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies, reported initiation of a Phase 1/2 clinical study of its potential best-in-class Nectin4/TROP2 bispecific antibody-drug conjugate, AVZO-103, in patients with advanced solid tumors (Press release, Avenzo Therapeutics, SEP 29, 2025, View Source [SID1234656315]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Nectin4 and TROP2 are highly co-expressed in multiple solid tumors, including urothelial cancer, and contribute to tumor growth and progression," said Benjamin Garmezy, M.D., Associate Director of Genitourinary Research, Sarah Cannon Research Institute. "By targeting both Nectin4 and TROP2, AVZO-103 has the potential to overcome tumor heterogeneity, while also delivering a potent cytotoxic payload that could help overcome resistance to prior therapies."

The Phase 1/2 first-in-human, open-label clinical study is designed to assess the safety, tolerability, and preliminary clinical activity of AVZO-103 as a single agent and in combination therapy in patients with advanced solid tumors.

"The initiation of this study marks our fourth clinical stage program at Avenzo, and reflects our commitment to advancing innovative therapies for patients with cancer," said Mohammad Hirmand, M.D., Co-founder and Chief Medical Officer of Avenzo Therapeutics. "We believe AVZO-103 potentially offers a differentiated approach to treating multiple solid tumors, especially urothelial cancer, and look forward to exploring its potential in the Phase 1/2 study."